We demonstrated that, in BLM (BRAF-wild type, NRAS-mutant) melanoma cells, ERβ agonists [17β-estradiol, diarylpropionitrile (DPN), KB1] significantly inhibited cell proliferation, and this effect was abrogated by an ER antagonist. This evidence concerns the gene ESR2 and melanoma.